ClinicalTrials.Veeva

Menu

Evaluation of Muscle Involvement in Systemic Sclerosis (MUSSc)

C

Central Hospital, Nancy, France

Status

Enrolling

Conditions

Systemic Sclerosis

Treatments

Other: muscle involvement

Study type

Observational

Funder types

Other

Identifiers

NCT06051773
2023PI160

Details and patient eligibility

About

Muscle involvement is poorly described in patients with systemic sclerosis (SSc) .

The prevalence of muscle damage is evaluated at 5-95 % of SSc patients, particularly due to variable definitions depending on the series in the scientific litterature. Muscle clinicobiological and histological presentation an response to immunosuppressive treatments are highly variable. Muscle involvement defined by creatinine kinase (CK) elevation, the presence of electromyography (EMG) abnormalities and/or muscle magnetic resonance imaging (MRI) hyperintensities and/or muscle biopsy inflammation appears to be associated with diffuse SSc, the presence of cardiac damage, and anti-PM-Scl antibodies.

The main objective is to describe muscular manifestations associated with SSc.

Secondary objectives are:

  • to compare characteristics between SSc patients with and without muscle involvement
  • to determine homogeneous groups of SSc patients with muscle involvement

Enrollment

150 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Patients with systemic sclerosis according to 2013 ACR/EULAR classification criteria

Trial design

150 participants in 1 patient group

SSc patients
Treatment:
Other: muscle involvement

Trial contacts and locations

1

Loading...

Central trial contact

Paul Decker, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems